Jupiter Neurosciences Files 8-K: Director Changes, Compensation Updates
Ticker: JUNS · Form: 8-K · Filed: Dec 22, 2025 · CIK: 1679628
Sentiment: neutral
Topics: governance, officer-compensation, corporate-actions
TL;DR
Jupiter Neurosciences 8-K: Director out, new director in, comp changes, bylaws updated, shareholder vote incoming.
AI Summary
On December 19, 2025, Jupiter Neurosciences, Inc. filed an 8-K report detailing several key events. The company announced the departure of a director, the election of a new director, and changes in officer compensation arrangements. Additionally, the filing covers amendments to the company's articles of incorporation or bylaws and the submission of matters to a vote of security holders. The report also includes financial statements and exhibits.
Why It Matters
This filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors, officer compensation, and corporate governance can indicate internal shifts or strategic realignments that may carry inherent risks.
Key Players & Entities
- Jupiter Neurosciences, Inc. (company) — Registrant
- December 19, 2025 (date) — Earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Jupiter Orphan Therapeutics, Inc. (company) — Former company name
- July 13, 2016 (date) — Date of former company name change
FAQ
Who departed from the board of directors?
The filing indicates the departure of a director, but the specific name is not provided in the excerpt.
Was a new director elected?
Yes, the filing states that a new director was elected.
What other items are covered in the 8-K filing?
The filing also covers changes to officer compensation, amendments to articles of incorporation or bylaws, and the submission of matters to a vote of security holders.
When was the earliest event reported in this filing?
The earliest event reported was on December 19, 2025.
What was Jupiter Neurosciences, Inc. formerly known as?
Jupiter Neurosciences, Inc. was formerly known as Jupiter Orphan Therapeutics, Inc.
Filing Stats: 1,520 words · 6 min read · ~5 pages · Grade level 11.1 · Accepted 2025-12-22 16:30:30
Key Financial Figures
- $0.0001 — f the Company's common stock, par value $0.0001 per share (the " Common Stock "), will
- $750,000 — mittees of the Board), shall not exceed $750,000 in total value, increased to $1,000,000
- $1,000,000 — d $750,000 in total value, increased to $1,000,000 for the first year of the director's se
- $20 million — d and outstanding Common Stock of up to $20 million of securities pursuant to the SEPA with
Filing Documents
- form8-k.htm (8-K) — 75KB
- ex3-1.htm (EX-3.1) — 10KB
- ex10-1.htm (EX-10.1) — 228KB
- 0001493152-25-028789.txt ( ) — 526KB
- juns-20251219.xsd (EX-101.SCH) — 3KB
- juns-20251219_lab.xml (EX-101.LAB) — 33KB
- juns-20251219_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 3.1 Certificate of Amendment to Certificate of Incorporation of Jupiter Neurosciences, Inc. 10.1 Jupiter Neurosciences, Inc. 2025 Equity Incentive Plan. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JUPITER NEUROSCIENCES, INC. By: /s/ Christer Rosn Christer Rosn Chief Executive Officer Date: December 22, 2025